Tempest Therapeutics (TPST) Current Assets (2011 - 2026)
Tempest Therapeutics (TPST) posted Current Assets of $8.3 million for Q4 2025, up 2.04% sequentially from $8.1 million in Q3 2025, and down 73.73% YoY from $31.5 million in Q4 2024.
Tempest Therapeutics (TPST) Current Assets (2011 - 2026) Analysis & Trends
Tempest Therapeutics has reported Current Assets for 15 years, with the latest figure at $8.3 million in Q4 2025.
- Quarterly Current Assets fell 73.73% year-over-year to $8.3 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $8.3 million (down 73.73% YoY) and the FY2025 annual result came in at $8.3 million, down 73.73% from the prior year.
- Current Assets climbed to $8.3 million in Q4 2025 per TPST's latest filing, from $8.1 million in the prior quarter.
- Over five years, Current Assets peaked at $70.5 million in Q2 2021 and troughed at $8.1 million in Q3 2025.
- A 5-year average of $38.3 million and a median of $32.2 million in 2022 frame the typical range for Current Assets.
- The sharpest annual moves came in 2021 and 2023: Current Assets surged 247.86% in 2021, then slumped 79.6% in 2023.
- Over 5 years, Current Assets stood at $69.0 million in 2021, then sank by 52.22% to $32.9 million in 2022, then rose by 22.5% to $40.4 million in 2023, then fell by 22.02% to $31.5 million in 2024, then tumbled by 73.73% to $8.3 million in 2025.
- According to Business Quant data, Current Assets over the past three periods registered $8.3 million, $8.1 million, and $15.1 million for Q4 2025, Q3 2025, and Q2 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 12.54 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 18.45 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 8.07 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 5.82 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 7.22 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 4.62 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 18.80 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 1.63 Bn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 1.76 Bn |
| 10 | Tempest Therapeutics | 4.32 Mn | 3.52 Mn | - | 1.70 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.70 Mn |
| Dec 31, 2025 | 8.27 Mn |
| Sep 30, 2025 | 8.10 Mn |
| Jun 30, 2025 | 15.10 Mn |
| Mar 31, 2025 | 22.43 Mn |
| Dec 31, 2024 | 31.47 Mn |
| Sep 30, 2024 | 23.55 Mn |
| Jun 30, 2024 | 31.55 Mn |
| Mar 31, 2024 | 33.50 Mn |
| Dec 31, 2023 | 40.36 Mn |
| Sep 30, 2023 | 12.29 Mn |
| Jun 30, 2023 | 18.54 Mn |
| Mar 31, 2023 | 24.67 Mn |
| Dec 31, 2022 | 32.95 Mn |
| Sep 30, 2022 | 60.26 Mn |
| Jun 30, 2022 | 68.31 Mn |
| Mar 31, 2022 | 62.71 Mn |
| Dec 31, 2021 | 68.96 Mn |
| Sep 30, 2021 | 62.56 Mn |
| Jun 30, 2021 | 70.49 Mn |